Clinical and Radiographic Success of MTA vs Biodentine

Pulpotomy Clinical Trial

Official title:

Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04863222
• Other study ID #: 2019-0994
• Status: Recruiting
• Phase: Phase 4
• Start date: November 12, 2021
• Est. completion date: July 1, 2025

Study information

• Verified date: February 2024
• Source: Geisinger Clinic
• Contact: Gayatri Malik, DMD
• Phone: 570-271-6355
• Email: gmalik1[@]geisinger.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Description:

This is a interventional randomized split mouth prospective study that evaluates the clinical and radiographic success of mineral trioxide aggregate (MTA) and Biodentine as pulpotomy and indirect pulp cap (IPC) medicaments. Male and female participants ages two to twelve who need at least two quadrants of treatment will be enrolled in the trial. Participants will be treated at Geisinger Medical Center, Danville, and Geisinger Bloomsburg Hospital operating rooms for full mouth rehabilitation. Each participant must have at least two matched bilateral carious primary molars that require either pulpotomy or indirect pulp cap. Maxillary and mandibular primary first and second molars who receive pulpotomy and /or indirect pulp cap will be compared. The research will be split mouth design where the primary molar on one side will get MTA as the pulpotomy or IPC medicament and the corresponding primary on the other side will get Biodentine as the pulpotomy or IPC medicament in the same arch.

The procedures will be performed according to standards of the American Academy of Pediatric Dentistry (AAPD), by Institutional Review Board approved investigators. Data will be extracted from the electronic health record (EHR) and TigerView dental radiograph imaging software. Data will be recorded using REDCap. Clinical and radiographic follow up of patients will be every 6 months since date of procedure for 3 years. Follow up will be done at the Geisinger Pediatric Dental Clinic at Danville or Milton.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 646
• Est. completion date: July 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years to 12 Years

Eligibility

Inclusion Criteria:

• Male or female patients ages of 2 to =12 years.

• Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.

• Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.

• Parents of patients who can provide consent in English.

• Patients who need treatment in an operating room setting at Geisinger.

Exclusion Criteria:

• Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.

• Radiographs not displaying furcation region of the tooth.

• Patients with cardiac conditions who need prophylaxis for infective Endocarditis.

• Patients with any type of cancer in the past or present.

• Non-restorable molars.

Related Conditions & MeSH terms

• Indirect Pulp Cap
• Pulpotomy

Intervention

Device:
• Biodentine
During a patients procedure, one tooth will receive Biodentine instead of MTA.

Biological:
• mineral trioxide aggregate (MTA)
mineral trioxide aggregate (MTA)

Locations

Country	Name	City	State
United States	Geisinger	Danville	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Geisinger Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of clinical success in pulpotomies and indirect pulp caps	To compare the rate of clinical success in primary molars using MTA versus Biodentine in pulpotomies and indirect pulp caps. Subjects will been seen at follow-up standard of care visits every 6 months for 3 years to clinically evaluate if the treatment was successful, if any discoloration has occurred and assess for any signs or symptoms of an abscess.	4 years
Primary	Rate of radiographic success in pulpotomies and indirect pulp caps	To compare the rate of radiographic success in primary molars using MTA versus Biodentine in pulpotomies and indirect pulp caps. Subjects will been seen at follow-up standard of care visits every 6 months for 3 years where x-rays will be taken to determine if any abscess have formed.	4 years